Marijn Dekkers, An apple a day is no longer enough, GCF2012 presentation


Published on

Marijn Dekkers, GCF2012 presentation, An apple a day is no longer enough

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Marijn Dekkers, An apple a day is no longer enough, GCF2012 presentation

  1. 1. GCF 2012 “ The Entrepreneurship Imperative” 21-24 January 2012 Dr. Marijn Dekkers Chairman of the Board of Management of Bayer AG An Apple A Day Is No Longer Enough?
  2. 2. Aging Population – In This Respect We Are Getting Healthier Source: OECD Increase of global average life expectancy Percent of global population aged 65 years+ Source: OECD
  3. 3. We Are Getting Healthier – Pharma Industry Contributions Source: IMS World Review, 1980-2010 *non-currency-adj. Pharma Industry with steady sales growth CAGR + 9 % Number of FDA-approved new pharmaceutical drugs Pharma Industry R&D–output on high level Adapted from: Munos, Lessons from 60 years of pharmaceutical innovation, Nature Reviews, December 2009. Global audited pharmaceutical drug sales* US$ bn *non-currency-adjusted
  4. 4. Source: The Global Burden Of Chronic Diseases, JAMA 2004 – Source derived from data in World Health Report 2003 *Chronic Obstructive Pulmonary Disease **Non-Communicable Diseases 0 10 20 30 40 50 60 1990 2002 2020 Cardiovascular Diseases Other NCD** COPD*, Asthma Diabetes Mellitus Chronic Illness – Global mortality vs. growth of world population Cancer At The Same Time Increase Of NCDs – Change Of Lifestyle 0 50 100 150 200 250 1963 1973 1983 1993 2003 Mio. t developing countries industrialized countries Source: Increase of global meat production NCDs +2% CAGR World population +1% CAGR No. of deaths mio.
  5. 5. Parallel Effect: Improved Diagnostics – More NCDs Diagnosed Computed Tomography exams USA, total Magnetic Resonance Imaging exams USA, total Number in Mio Source: OECD
  6. 6. Pharma Innovation At Bayer What it does Status Cardiology Xarelto ® Prevents Thrombosis <ul><li>Approved in U.S. EU and Japan for prevention of stroke </li></ul>Riociguat Lowers Blood pressure in the Lung <ul><li>Results of clinical phase III study expected December 2012 </li></ul>Oncology Regorafenib Inhibits Tumor Growth <ul><li>Phase III study on colorectal cancer successful </li></ul><ul><li>Application for approval planned in Q2 2012 </li></ul>Alpharadin Targeted treatment of bone metastases in prostate cancer <ul><li>Phase III study successful </li></ul><ul><li>Application for approval planned in Q2 2012 </li></ul>Ophthal- mology VEGF Trap-Eye Prevents irregular blood vessels in the back of the eye <ul><li>Approved in the U.S. for wet AMD </li></ul><ul><li>Approval in EU expected June 2012 </li></ul>
  7. 7. Continuous Effort Required – Significant Medical Need Re. NCDs Will Persist Top 10 killers worldwide Source: McKinsey <ul><li>Ischaemic heart disease </li></ul><ul><li>Cerebrovascular disease </li></ul><ul><li>Lower respiratory infections </li></ul><ul><li>Chronic obstructive pulmonary disease </li></ul><ul><li>HIV/AIDS </li></ul><ul><li>Diarrhoeal diseases </li></ul><ul><li>Tuberculosis </li></ul><ul><li>Respiratory cancers </li></ul><ul><li>Childhood-cluster diseases </li></ul><ul><li>Hypertensive heart disease </li></ul><ul><li>Ischaemic heart disease </li></ul><ul><li>Cerebrovascular disease </li></ul><ul><li>HIV/AIDS </li></ul><ul><li>Chronic obstructive pulmonary disease </li></ul><ul><li>Lower respiratory infections </li></ul><ul><li>Respiratory cancers </li></ul><ul><li>Stomach cancer </li></ul><ul><li>Hypertensive heart disease </li></ul><ul><li>Nephritis and nephrosis </li></ul><ul><li>Liver cancer </li></ul>10. 10. 2030 2005
  8. 8. Rising R&D Expenditures – Adequate Rewards? Source: FDA, PhRMA, Bank of Amerika Merrill-Lynch Global Research Worldwide R&D spending (indexed, 1996 = 100) FDA approvals new pharmaceutical drugs (indexed, 1996=100)
  9. 9. Dr. Marijn Dekkers Chairman of the Board of Management of Bayer AG